Roadshow
PCR-CE FMR1 & Thalassemia kit
This panel combines Fragile X Syndrome and thalassemia testing into a unified PCR-CE solution. The FMR1 assay delivers accurate quantification of CGG repeats—including full mutations exceeding 200 repeats—with exceptional amplification stability and result reproducibility.
The thalassemia assay distinguishes over eight α-thalassemia deletions, three α-point mutations, 17 β-thalassemia hotspots, and large deletions in a single-tube workflow. Results are available in 4–5.5 hours with high throughput and diagnostic precision. This comprehensive panel supports both carrier screening and confirmatory diagnostics, offering a powerful alternative to MLPA and TGS platforms.
- Established 2018
- Company Origin Biotechnology., Ltd.
- Telephone +886 02-3393-1118#12
- Email yuwei@oribio.com.tw
- Address 5F.-1, No. 12, Linsen S. Rd., Zhongzheng Dist., Taipei, Taiwan
Origin is an innovative biotechnology company based on autonomous research and development to the field of molecular diagnostics. Our business strategy aims to develop rapid, accurate IVD kit to fulfill unresolved clinical demands. Our mission focus on prevention, screening, and diagnose of gynecological, pediatric, and genetic disease. Origin have recently made significant breakthroughs in developing a comprehensive panel for genetic disease testing and a full-scope fragment analysis solution, offering an advanced alternative to the current CNV gold standard. Our product portfolio demonstrates outstanding performance in FXS, SMA, and Thalassemia testing in both specifications and coverage. Moreover, we offer the world’s first and only IVD assay for Kawasaki Disease, addressing an urgent unmet need in pediatric diagnostics.